Literature DB >> 1599018

Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma.

K Chang1, L H Pai, H Pass, H W Pogrebniak, M S Tsao, I Pastan, M C Willingham.   

Abstract

Immunoperoxidase histochemical staining of cryostat sections from human tumor tissues revealed that a murine monoclonal antibody (MAb), K1, can distinguish epithelial mesotheliomas from lung adenocarcinomas. All of 15 epithelial-type mesotheliomas and all four mixed type mesothelioma samples, but none of 23 lung adenocarcinomas with different degrees of histologic differentiation demonstrated reactivity with antibody K1. Of the cell populations in each mesothelioma tested, 80% to 100% showed strong and homogeneous staining with MAb K1. Immunofluorescence analysis of live cultured cells from an epithelioid mesothelioma (H-meso) and several lung carcinoma cell lines as well as a pleural effusion of a patient with mesothelioma also showed selective reactivity of K1 with the mesothelioma cells. These data indicate that K1 can be useful as a mesothelial cell marker for the differential pathological diagnosis of the epithelial form of mesothelioma; K1 may also be useful in the study of the pathogenesis, immunodiagnosis, and immunotherapy of epithelial-type and mixed-type human malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1599018     DOI: 10.1097/00000478-199203000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  39 in total

1.  Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.

Authors:  Tapan K Bera; Wenlong Liu; Jasmin Leshem; Emily King; Serguei Kozlov; Ira Pastan
Journal:  J Immunother       Date:  2019-05       Impact factor: 4.456

2.  Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.

Authors:  Jonathan Villena-Vargas; Prasad S Adusumilli
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 3.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

4.  Diagnostic tumor marker of asbestos-related mesothelioma.

Authors:  Okio Hino; Masahiro Maeda
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

Review 5.  Advances in anticancer immunotoxin therapy.

Authors:  Christine Alewine; Raffit Hassan; Ira Pastan
Journal:  Oncologist       Date:  2015-01-05

6.  Role of p16 deletion and BAP1 loss in the diagnosis of malignant mesothelioma.

Authors:  Jing Liu; Xuanzhi Liao; Yingying Gu; Lin Fu; Jin Zhao; Longguang Li; Zhucheng Chen; Juhong Jiang
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 7.  Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.

Authors:  Mitchell Ho
Journal:  BioDrugs       Date:  2011-10-01       Impact factor: 5.807

8.  Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.

Authors:  Jingli Zhang; Shuo Qiu; Yujian Zhang; Maria Merino; Patricia Fetsch; Itzhak Avital; Armando Filie; Ira Pastan; Raffit Hassan
Journal:  Anticancer Res       Date:  2012-12       Impact factor: 2.480

9.  Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.

Authors:  Prince Awuah; Tapan K Bera; Messan Folivi; Oleg Chertov; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261

Review 10.  Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

Authors:  Mark O'Hara; Caitlin Stashwick; Andrew R Haas; Janos L Tanyi
Journal:  Immunotherapy       Date:  2016       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.